On the molecular level, the metabolic syndrome in association with insulin resistance seems a key player in NASH, driving activation of sterol regulatory element-binding protein 1 (SREBP-1c), the major activator of hepatic de novo lipogenesis and triglyceride synthesis. Here, SREBF1 is linked to metabolic syndrome.